RE:RE:RE:Q-3 Nothing exciting as expected and no ugly surprises which is nice. Cash is best ever and antigen demand returning. The focus in Q2/3 has been preparing for transformative Q4 which yesterdays announcement (finally!) confirms is not a pipe dream. The first of many hopefully. VTM and antigens are a side show compared to QAPs potential but key contributors and diversifiers. Kinlytic remains a potential huge upside surprise. If they can keep signing new QAPs deals fourth site could become a reality soon and if that happens look out because that same template could be used over and over as the business grows. Setup costs are low and volumes and margins are huge. Watch for any fourth building announcement or discussion of it next week as moving forward on this will confirm that this conservative management team is confident in huge QAPs volumes and revenues and have the customers and contracts awaiting capacity.